Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03596450 · ClinicalTrials.gov registry record · Phase 4
Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial
A Phase 4 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 4
- Development phase
- 1,278
- Enrollment target
NCT03596450 is a Phase 4 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 1,278 participants.
The verdict
NCT03596450, a Phase 4 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1,278 participants
- Enrollment target
Study Summary
The main purpose of this study is to compare the effects of semaglutide (Ozempic®) with the effects of other treatments for type 2 diabetes in a normal practice setting. The participant will be assigned by chance (like flipping a coin) to one of the following treatment groups: Group 1: semaglutide (Ozempic®) (by injection into skin) Group 2: standard of care antidiabetic medication (oral or injectable). The participant has an equal chance of being in either of the treatment groups. Neither the participant nor the study doctor or study staff will be able to pick which group the participant is in, but the participant will know which study drug the participant has been assigned to. The study doctor will provide the participant with a prescription for the study diabetes medication based on the treatment group the participant is assigned. The participation will last about 2 years.
Interventions
- DRUG Semaglutide
- DRUG Standard of care
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,278 participants |
| Start Date | 2018-07-13 |
| Est. Completion | 2023-06-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03596450
The ClinicalTrials.gov registry entry for NCT03596450 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 1,278 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Semaglutide is the first listed.
NCT03596450 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03596450 about?
NCT03596450 is a clinical study titled "Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial". The main purpose of this study is to compare the effects of semaglutide (Ozempic®) with the effects of other treatments for type 2 diabetes in a normal practice setting. The participant will be assigned by chance (like flipping a coin) to one of the following treatment groups: Group 1: semaglutide (...
What is the current status of trial NCT03596450?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,278 participants. The study started on 2018-07-13. Estimated completion is 2023-06-09.
What interventions are being tested in trial NCT03596450?
The interventions under investigation include: Semaglutide (DRUG), Standard of care (DRUG).
Who is sponsoring clinical trial NCT03596450?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.